Abstract: A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule.

Abstract: A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule.

Abstract: A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming a multilamellar liposome, or non-lipid molecule capable of forming a vesicle or gel. A therapeutically effective amount of at least one cell-based immunotherapeutic agent is also administered to the patient before, after, or at the same time the vaccine is administered to the patient.

Abstract: A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming a multilamellar liposome, or non-lipid molecule capable of forming a vesicle or gel. A therapeutically effective amount of at least one cell-based immunotherapeutic agent is also administered to the patient before, after, or at the same time the vaccine is administered to the patient.

Abstract: A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule.

Abstract: Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.

Abstract: The invention describes a Lipomatrix composed of lipid lattices of stacked bilayers which, when hydrated, form liposomes. The invention also provides a simplified method used to generate highly effective liposomal preparations. Vaccine compositions having superior immunological properties use biomedical-grade liposomes which can be produced from a Lipomatrix, using safe and efficient methods. Use of the inventive methods produces highly potent vaccines against tumor antigens.

Abstract: Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.

Abstract: Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.